The 21st Century Cures Act has sparked debate since its passage in the last days of the Obama presidency. The law promises to ramp up funding for biomedical research while it also loosens regulations governing drugs and medical devices. Supporters say it will speed up approval of new treatments, while critics are concerned that the safety and effectiveness may be compromised.

To debate these points and other implications of the law — whose implementation will be a major priority for the new FDA commissioner soon to be appointed by President Trump — the Forum at the Harvard T.H. Chan School of Public Health invited experts to participate in an hour-long panel discussion. Presented jointly with STAT, the event video is below.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy